Get the Stockscreener App
8.57
1.54%
0.13
After Hours:
8.57
Nurix Therapeutics Inc stock is traded at $8.57, with a volume of 1.32M.
It is up +1.54% in the last 24 hours and down -19.00% over the past month.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
See More
Previous Close:
$8.44
Open:
$8.53
24h Volume:
1.32M
Relative Volume:
1.61
Market Cap:
$655.17M
Revenue:
$54.55M
Net Income/Loss:
$-193.57M
P/E Ratio:
-2.9654
EPS:
-2.89
Net Cash Flow:
$-181.86M
1W Performance:
-4.25%
1M Performance:
-19.00%
6M Performance:
-38.48%
1Y Performance:
-65.49%
1-Day Range:
$8.455
$9.06
1-Week Range:
$8.33
$9.25
52-Week Range:
$8.18
$29.56
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Name
Nurix Therapeutics Inc
Sector
Industry
Phone
(415) 660-5320
Address
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
Compare NRIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
8.57 | 645.23M | 54.55M | -193.57M | -181.86M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.15 | 100.34B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.50 | 60.95B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.73 | 60.46B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
734.35 | 46.04B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
332.20 | 36.02B | 3.81B | -644.79M | -669.77M | -6.24 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-25 | Initiated | Leerink Partners | Market Perform |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-11-24 | Initiated | Jefferies | Buy |
| Sep-06-24 | Resumed | Robert W. Baird | Outperform |
| Jul-31-24 | Initiated | Truist | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-09-23 | Initiated | Barclays | Overweight |
| Feb-28-23 | Initiated | Oppenheimer | Outperform |
| Oct-11-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-31-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Dec-29-21 | Initiated | H.C. Wainwright | Buy |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-30-21 | Resumed | Piper Sandler | Overweight |
| Apr-30-21 | Initiated | RBC Capital Mkts | Outperform |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Nov-19-20 | Initiated | Robert W. Baird | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
| Aug-18-20 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-18-20 | Initiated | Stifel | Buy |
View All
Nurix Therapeutics Inc Stock (NRIX) Latest News
Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis - The Manila Times
Nurix Therapeutics Advances GS-6791 into Clinical Testing for Inflammatory Diseases with Preclinical Data Presented at EADV Congress - Quiver Quantitative
Near-Complete IRAK4 Knockdown: Nurix's Novel Dermatitis Drug Shows Breakthrough Results in Preclinical Study - Stock Titan
Goldman Sachs Group Inc. Raises Stock Holdings in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Aug Volume: Should I buy Nurix Therapeutics Inc stock nowWeekly Profit Recap & Weekly Chart Analysis and Trade Guides - خودرو بانک
Earnings Report: Is Nurix Therapeutics Inc. stock good for income investorsWeekly Trade Recap & Fast Exit/Entry Strategy Plans - خودرو بانک
Aug Summary: What is the long term forecast for Nurix Therapeutics Inc stock2025 Investor Takeaways & Daily Profit Maximizing Tips - خودرو بانک
Inflation Data: Is Nurix Therapeutics Inc a stock for growth or value investorsJuly 2025 Catalysts & Reliable Volume Spike Trade Alerts - خودرو بانک
Sentiment Recap: Why is Nurix Therapeutics Inc stock going downIPO Watch & Verified Chart Pattern Trade Signals - خودرو بانک
Market Outlook: Why is Nurix Therapeutics Inc stock going downWall Street Watch & AI Powered Market Entry Ideas - خودرو بانک
Geopolitics Watch: Will Nurix Therapeutics Inc outperform the market in YEARJuly 2025 Spike Watch & Short-Term Trading Opportunity Alerts - خودرو بانک
Nurix Therapeutics (NASDAQ:NRIX) Trading Down 6.5%Should You Sell? - MarketBeat
Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation - 富途牛牛
Transcript : Nurix Therapeutics, Inc. Presents at Baird Global Healthcare Conference 2025, Sep-09-2025 10 - MarketScreener
Cinctive Capital Management LP Sells 120,202 Shares of Nurix Therapeutics, Inc. $NRIX - MarketBeat
Transcript : Nurix Therapeutics, Inc. Presents at Morgan Stanley 23rd Annual Global Healthcare Conference, Sep-10-2025 07 - MarketScreener
Parkman Healthcare Partners LLC Cuts Stock Holdings in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Nurix Therapeutics : investor deck Baird - MarketScreener
Nurix Therapeutics : investor deck HCW Final - MarketScreener
Vestal Point Capital LP Boosts Stake in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Does Nurix Therapeutics Inc. have a sustainable dividendWeekly Trade Summary & Step-by-Step Swing Trade Plans - beatles.ru
Redmile Group LLC Has $48.14 Million Position in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Invesco Ltd. Purchases 65,655 Shares of Nurix Therapeutics, Inc. $NRIX - MarketBeat
Combining machine learning predictions for Nurix Therapeutics Inc.Quarterly Portfolio Report & Proven Capital Preservation Methods - Newser
Applying Elliott Wave Theory to Nurix Therapeutics Inc.Long Setup & Risk Controlled Daily Trade Plans - Newser
Does Nurix Therapeutics Inc. show high probability of reboundRisk Management & Daily Risk Controlled Trade Plans - Newser
Using economic indicators to assess Nurix Therapeutics Inc. potentialQuarterly Risk Review & Daily Price Action Insights - Newser
What high frequency data says about Nurix Therapeutics Inc.July 2025 Macro Moves & Smart Allocation Stock Reports - Newser
Market reaction to Nurix Therapeutics Inc.’s recent news2025 Key Lessons & Growth Focused Entry Reports - Newser
Walleye Capital LLC Invests $880,000 in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Applying Wyckoff theory to Nurix Therapeutics Inc. stockMarket Performance Recap & Stock Timing and Entry Methods - Newser
Key resistance and support levels for Nurix Therapeutics Inc.Market Performance Report & Daily Risk Controlled Trade Plans - Newser
Published on: 2025-09-05 13:16:55 - Newser
Is it time to cut losses on Nurix Therapeutics Inc.2025 Market Sentiment & Free Safe Capital Growth Stock Tips - Newser
Will breakout in Nurix Therapeutics Inc. lead to full recoveryJuly 2025 Trade Ideas & Technical Entry and Exit Alerts - Newser
What to do if you’re stuck in Nurix Therapeutics Inc.July 2025 Momentum & Accurate Trade Setup Notifications - Newser
Driehaus Capital Management LLC Sells 563,751 Shares of Nurix Therapeutics, Inc. $NRIX - MarketBeat
Analyzing Nurix Therapeutics Inc. with multi timeframe chartsMarket Sentiment Report & Free Low Drawdown Momentum Trade Ideas - Newser
Is this a good reentry point in Nurix Therapeutics Inc.July 2025 Outlook & Daily Entry Point Alerts - Newser
Analyzing drawdowns of Nurix Therapeutics Inc. with statistical toolsMarket Trend Report & Growth-Oriented Investment Plans - Newser
Sector ETF performance correlation with Nurix Therapeutics Inc.Inflation Watch & Verified Short-Term Trading Plans - Newser
Nuveen LLC Makes New Investment in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Nurix Therapeutics to Discuss Bexobrutideg Developments - The Globe and Mail
Tema Etfs LLC Increases Stake in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Understanding Nurix Therapeutics Inc.’s price movementJuly 2025 Catalysts & Detailed Earnings Play Strategies - Newser
Technical signs of recovery in Nurix Therapeutics Inc.2025 Technical Patterns & Precise Buy Zone Identification - Newser
Visual analytics tools that track Nurix Therapeutics Inc. performancePrice Action & Free Technical Confirmation Trade Alerts - Newser
What machine learning models say about Nurix Therapeutics Inc.2025 Price Momentum & High Return Stock Watch Alerts - Newser
Applying big data sentiment scoring on Nurix Therapeutics Inc.2025 Big Picture & Fast Gaining Stock Reports - Newser
Using R and stats models for Nurix Therapeutics Inc. forecastingGold Moves & Short-Term Trading Alerts - Newser
Nurix Therapeutics Inc Stock (NRIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.62%
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):